Tirbanibulin (Klisyri)
Overview
Tirbanibulin is a small molecule synthetic peptide mimetic that inhibits tubulin polymerization and disrupts Src kinase signaling pathways. It is applied topically as a 1% ointment to treat actinic keratosis, a precancerous skin condition caused by chronic sun exposure.
Mechanism of Action
The dual mechanism targets both the cytoskeleton and oncogenic signaling in hyperproliferative keratinocytes. Its localized application minimizes systemic exposure while achieving targeted antiproliferative effects..
Research Summary & Key Findings
Two phase III trials (KX01-AK-003 and KX01-AK-004) demonstrated superior complete clearance of actinic keratosis lesions compared to vehicle, with a five-day treatment course (Journal of the American Academy of Dermatology, 2021). The FDA approved tirbanibulin in December 2020 for topical treatment of actinic keratosis on the face or scalp. Post-marketing use has confirmed favorable tolerability with primarily local skin reactions.
Clinical Status
Tirbanibulin (Klisyri) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
Related Peptides in Oncology
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...
View detailsBortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...
View detailsLutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...
View detailsLeuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...
View detailsFind a Provider
Find a verified provider who offers Tirbanibulin (Klisyri) therapy in your area.
Browse Provider MapFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Tirbanibulin (Klisyri).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.